secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001549595-24-000160
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025
--------------------------------------------------------------------------------

- ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.
- Median duration of response not reached; 13 patients >6 months, 5 >1 year on treatment.
- Well tolerated; only 1 grade 1 atrial fibrillation; common AEs: purpura/contusion, fatigue, petechiae, neutropenia.
- Responses across baseline BTK (38.6%), PLCG2 (12.3%), TP53 (40.4%) mutations and CNS involvement (5 patients).
- Company on track to initiate pivotal trials of NX-5948 in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000160/0001549595-24-000160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000160/nrix-20241209.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer